{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:55:42Z","timestamp":1776426942391,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10157-026-02845-6","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:19:04Z","timestamp":1773674344000},"page":"747-756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-8735","authenticated-orcid":false,"given":"Yukihiro","family":"Wada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Togo","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"4","key":"2845_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1515920.","journal-title":"N Engl J Med"},{"issue":"24","key":"2845_CR2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"15","key":"2845_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"8","key":"2845_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/s2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605\u201317. https:\/\/doi.org\/10.1016\/s2213-8587(18)30104-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2845_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"key":"2845_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109231","volume":"185","author":"K Kobayashi","year":"2022","unstructured":"Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Chin K, et al. Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Diabetes Res Clin Pract. 2022;185:109231. https:\/\/doi.org\/10.1016\/j.diabres.2022.109231.","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"2845_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/1753-0407.12514","volume":"9","author":"HF Chung","year":"2017","unstructured":"Chung HF, Al Mamun A, Huang MC, Long KZ, Huang YF, Shin SJ, et al. Obesity, weight change, and chronic kidney disease in patients with type 2 diabetes mellitus: a longitudinal study in Taiwan. J Diabetes. 2017;9(11):983\u201393. https:\/\/doi.org\/10.1111\/1753-0407.12514.","journal-title":"J Diabetes"},{"issue":"1","key":"2845_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jcjd.2021.05.005","volume":"46","author":"Y Xia","year":"2022","unstructured":"Xia Y, Jiang C, Lu J, Liu J, Gu T, Bi Y. Associations between obesity and kidney disease in Chinese men and women with type 2 diabetes: a retrospective cohort study. Can J Diabetes. 2022;46(1):47-52 e3. https:\/\/doi.org\/10.1016\/j.jcjd.2021.05.005.","journal-title":"Can J Diabetes"},{"key":"2845_CR9","unstructured":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266."},{"issue":"6","key":"2845_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2845_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7326\/m20-0529","volume":"173","author":"K Sumida","year":"2020","unstructured":"Sumida K, Nadkarni GN, Grams ME, Sang Y, Ballew SH, Coresh J, et al. Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis. Ann Intern Med. 2020;173(6):426\u201335. https:\/\/doi.org\/10.7326\/m20-0529.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2845_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150\u201361. https:\/\/doi.org\/10.1002\/pst.433.","journal-title":"Pharm Stat"},{"issue":"6","key":"2845_CR13","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1111\/dom.15561","volume":"26","author":"Y Suzuki","year":"2024","unstructured":"Suzuki Y, Kaneko H, Nagasawa H, Okada A, Fujiu K, Jo T, et al. Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: a propensity-score matching study. Diabetes Obes Metab. 2024;26(6):2422\u201330. https:\/\/doi.org\/10.1111\/dom.15561.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2845_CR14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","volume":"84","author":"D Edmonston","year":"2024","unstructured":"Edmonston D, Mulder H, Lydon E, Chiswell K, Lampron Z, Shay C, et al. Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes. J Am Coll Cardiol. 2024;84(8):696\u2013708. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.016.","journal-title":"J Am Coll Cardiol"},{"key":"2845_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109146","volume":"183","author":"Y Kawai","year":"2022","unstructured":"Kawai Y, Uneda K, Yamada T, Kinguchi S, Kobayashi K, Azushima K, et al. Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with\/without albuminuria: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2022;183:109146. https:\/\/doi.org\/10.1016\/j.diabres.2021.109146.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2845_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0125-x","volume":"18","author":"S Kawasoe","year":"2017","unstructured":"Kawasoe S, Maruguchi Y, Kajiya S, Uenomachi H, Miyata M, Kawasoe M, et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol. 2017;18(1):23. https:\/\/doi.org\/10.1186\/s40360-017-0125-x.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"2845_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3164\/jcbn.21-153","volume":"71","author":"N Itoh","year":"2022","unstructured":"Itoh N, Tsuya A, Togashi H, Kimura H, Konta T, Nemoto K, et al. Increased salt intake is associated with diabetes and characteristic dietary habits: a community-based cross-sectional study in Japan. J Clin Biochem Nutr. 2022;71(2):143\u201350. https:\/\/doi.org\/10.3164\/jcbn.21-153.","journal-title":"J Clin Biochem Nutr"},{"issue":"4","key":"2845_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/cob.70012","volume":"15","author":"A Ali","year":"2025","unstructured":"Ali A, Siddiqui AA, Usman MS, Shahid I, Khan MS, Perswani P. Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: a systematic review and network meta-analysis. Clin Obes. 2025;15(4):e70012. https:\/\/doi.org\/10.1111\/cob.70012.","journal-title":"Clin Obes"},{"issue":"2","key":"2845_CR19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/hjh.0000000000003903","volume":"43","author":"HJ Wong","year":"2025","unstructured":"Wong HJ, Toh KZX, Teo YH, Teo YN, Chan MY, Yeo LLL, et al. Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials. J Hypertens. 2025;43(2):290\u2013300. https:\/\/doi.org\/10.1097\/hjh.0000000000003903.","journal-title":"J Hypertens"},{"issue":"5","key":"2845_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2337\/dc19-1745","volume":"43","author":"WT Garvey","year":"2020","unstructured":"Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085\u201393. https:\/\/doi.org\/10.2337\/dc19-1745.","journal-title":"Diabetes Care"},{"issue":"2","key":"2845_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","volume":"48","author":"HJ Wong","year":"2025","unstructured":"Wong HJ, Sim B, Teo YH, Teo YN, Chan MY, Yeo LLL, et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care. 2025;48(2):292\u2013300. https:\/\/doi.org\/10.2337\/dc24-1678.","journal-title":"Diabetes Care"},{"issue":"10","key":"2845_CR22","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1111\/dom.15808","volume":"26","author":"T Jimba","year":"2024","unstructured":"Jimba T, Kaneko H, Azegami T, Suzuki Y, Okada A, Ko T, et al. Body weight change associated kidney outcomes of sodium-glucose cotransporter new users. Diabetes Obes Metab. 2024;26(10):4535\u201343. https:\/\/doi.org\/10.1111\/dom.15808.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"2845_CR23","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/ndt\/gfv219","volume":"30","author":"A Chang","year":"2015","unstructured":"Chang A, Greene TH, Wang X, Kendrick C, Kramer H, Wright J, et al. The effects of weight change on glomerular filtration rate. Nephrol Dial Transplant. 2015;30(11):1870\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfv219.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"2845_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137163","volume":"10","author":"B Zingerman","year":"2015","unstructured":"Zingerman B, Herman-Edelstein M, Erman A, Bar Sheshet Itach S, Ori Y, Rozen-Zvi B, et al. Effect of acetazolamide on obesity-induced glomerular hyperfiltration: a randomized controlled trial. PLoS ONE. 2015;10(9):e0137163. https:\/\/doi.org\/10.1371\/journal.pone.0137163.","journal-title":"PLoS ONE"},{"issue":"4","key":"2845_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/circulationaha.123.064346","volume":"148","author":"M Packer","year":"2023","unstructured":"Packer M, Wilcox CS, Testani JM. Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing Heart Failure outcomes. Circulation. 2023;148(4):354\u201372. https:\/\/doi.org\/10.1161\/circulationaha.123.064346.","journal-title":"Circulation"},{"issue":"5","key":"2845_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04289-z","volume":"79","author":"R La Grotta","year":"2022","unstructured":"La Grotta R, de Candia P, Olivieri F, Matacchione G, Giuliani A, Rippo MR, et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cell Mol Life Sci. 2022;79(5):273. https:\/\/doi.org\/10.1007\/s00018-022-04289-z.","journal-title":"Cell Mol Life Sci"},{"key":"2845_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2147\/dmso.s399343","volume":"16","author":"M Dong","year":"2023","unstructured":"Dong M, Chen H, Wen S, Yuan Y, Yang L, Xu D, et al. The mechanism of Sodium-Glucose Cotransporter-2 inhibitors in reducing uric acid in Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2023;16:437\u201345. https:\/\/doi.org\/10.2147\/dmso.s399343.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"2845_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02539-x","volume":"23","author":"C Morciano","year":"2024","unstructured":"Morciano C, Gugliandolo S, Capece U, Di Giuseppe G, Mezza T, Ciccarelli G, et al. SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives. Cardiovasc Diabetol. 2024;23(1):449. https:\/\/doi.org\/10.1186\/s12933-024-02539-x.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2845_CR29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Ruan B, Jiang H, Le S, Liu Y, Ao X, et al. The weight-loss effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr. 2023;118(3):614\u201326. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.04.017.","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"2845_CR30","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","volume":"138","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. Mechanisms of GLP-1 Receptor Agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025;138(6):934\u201340. https:\/\/doi.org\/10.1016\/j.amjmed.2025.01.021.","journal-title":"Am J Med"},{"issue":"4","key":"2845_CR31","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.31662\/jmaj.2025-0224","volume":"8","author":"Y Muta","year":"2025","unstructured":"Muta Y, Kobayashi K, Toyoda M, Sotozawa M, Chiba K, Senda Y, et al. Sex differences in renal outcomes and metabolic markers by combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a post-hoc analysis of the RECAP study. JMA J. 2025;8(4):1269\u201375. https:\/\/doi.org\/10.31662\/jmaj.2025-0224.","journal-title":"JMA J"},{"issue":"6","key":"2845_CR32","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.pcd.2021.08.012","volume":"15","author":"K Kobayashi","year":"2021","unstructured":"Kobayashi K, Toyoda M, Hatori N, Sato K, Miyakawa M, Tamura K, et al. The evaluation of noninferiority for renal composite outcomes between sodium-glucose cotransporter inhibitors in Japan. Prim Care Diabetes. 2021;15(6):1058\u201362. https:\/\/doi.org\/10.1016\/j.pcd.2021.08.012.","journal-title":"Prim Care Diabetes"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02845-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02845-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02845-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:09:33Z","timestamp":1776424173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02845-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2845"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02845-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yukihiro Wada reports payment or honoraria from DAIICHI SANKYO and Nippon Boehringer Ingelheim Co., Ltd. Masao Toyoda reports grants or contracts from LifeScan Japan, Mitsubishi Tanabe, DAIICHI SANKYO, Novo Nordisk, Sanofi, Takeda, Eli Lilly, MSD, Roche, and Dexcom, and payment or honoraria from Taisho, Kissei, Medtronic, Terumo, Abbott, MSD, Eli Lilly, Novartis, Takeda, Sumitomo, Sanofi, Novo Nordisk, Daiich Sankyo, Mitsubishi Tanabe, Ono, Boehringer Ingelheim, AstraZeneca, Astellas, Kyowa Kirin, Kowa. Kazuo Kobayashi reports payment or honoraria from Novartis Pharmacy and Otsuka Pharmacy. Togo Aoyama reports payment or honoraria from Nippon Boehringer Ingelheim Co., Ltd. The other authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the Special Ethics Committee of the Kanagawa Medical Association, Japan. Approval for the SGLT2i survey was obtained on March 6, 2018 (approval no. Krec304401), and approval for the GLP-1Ra survey and the present comparison study was granted on March 23, 2020 (approval no. Krec202005).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No animals were involved in this research so a statement on their welfare does not apply.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}